Cyrcadia is an innovative wearable medical device that screens for breast cancer using AI to detect metabolic changes in breast tissue that correlate to malignant tumor formation.
Rouse supported the negotiation with the US parent company for formation of special-purpose vehicles for licensing the technology into the Asia-Pacific. It negotiated key agreements for the company with suppliers, clinical institutions and other commercial partners and managed its IP portfolio Rouse supported due diligence and negotiations around Cyrcadia’s Seed round funding, where the company secured $3.6M, lead by one of China’s AI champions, iFlytek. Rouse acts as legal and commercial advisor to the company on an ongoing basis.
Rob Royea, CEO and Chairman “Chris and his team were instrumental in structuring the licensing and JV deal to form Cyrcadia Asia, to support the company to establish several of its key strategic relationship and obtain funding”.
